151 related articles for article (PubMed ID: 31748806)
1. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis.
Nguyen NH; Kurnool S; Dulai PS; Boland BS; Sandborn WJ; Singh S
Inflamm Bowel Dis; 2020 Aug; 26(9):1429-1435. PubMed ID: 31748806
[TBL] [Abstract][Full Text] [Related]
2. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
Kurnool S; Nguyen NH; Proudfoot J; Dulai PS; Boland BS; Vande Casteele N; Evans E; Grunvald EL; Zarrinpar A; Sandborn WJ; Singh S
Aliment Pharmacol Ther; 2018 Jun; 47(11):1472-1479. PubMed ID: 29665045
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N
Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478
[TBL] [Abstract][Full Text] [Related]
4. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
5. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
[TBL] [Abstract][Full Text] [Related]
6. P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.
Dalal R; Mitri J; Goodrick H; Allegretti J
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S19. PubMed ID: 37461990
[TBL] [Abstract][Full Text] [Related]
7. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
Lee SH; Walshe M; Oh EH; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Greener T; Weizman AV; Silverberg MS; Ye BD
Inflamm Bowel Dis; 2021 Aug; 27(9):1452-1461. PubMed ID: 33269403
[TBL] [Abstract][Full Text] [Related]
8. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
9. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.
Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
Clin Transl Gastroenterol; 2021 Jul; 12(7):e00380. PubMed ID: 34228004
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
[TBL] [Abstract][Full Text] [Related]
11. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
[TBL] [Abstract][Full Text] [Related]
12. Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis.
Yuan W; Marwaha JS; Rakowsky ST; Palmer NP; Kohane IS; Rubin DT; Brat GA; Feuerstein JD
Inflamm Bowel Dis; 2023 May; 29(5):695-704. PubMed ID: 35786768
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
14. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
15. Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.
Sartini A; Scaioli E; Liverani E; Bellanova M; Ricciardiello L; Bazzoli F; Belluzzi A
Dig Dis Sci; 2019 Mar; 64(3):863-874. PubMed ID: 30334112
[TBL] [Abstract][Full Text] [Related]
16. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
[TBL] [Abstract][Full Text] [Related]
17. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
18. Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany.
Bokemeyer B; Picker N; Kromer D; Rosin L; Patel H
Int J Colorectal Dis; 2023 May; 38(1):116. PubMed ID: 37150784
[TBL] [Abstract][Full Text] [Related]
19. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
20. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.
Rosen MJ; Karns R; Vallance JE; Bezold R; Waddell A; Collins MH; Haberman Y; Minar P; Baldassano RN; Hyams JS; Baker SS; Kellermayer R; Noe JD; Griffiths AM; Rosh JR; Crandall WV; Heyman MB; Mack DR; Kappelman MD; Markowitz J; Moulton DE; Leleiko NS; Walters TD; Kugathasan S; Wilson KT; Hogan SP; Denson LA
Gastroenterology; 2017 May; 152(6):1345-1357.e7. PubMed ID: 28132889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
